CytoMed Therapeutics Limited (GDTC)
GDTC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1873093/000149315226013813/0001493152-26-013813-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31. Converted from SGD at 1.2826 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | GDTC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Singapore |
| IPO year | 2023 |
| SEC CIK | 0001873093 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | U0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $253K |
| Net income | -$3.1M |
| Operating income | Not in SEC XBRL data |
| Net margin | -1227.1% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 40.7× |
Reported in SGD; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-08-18 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 130 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BIVI | BioVie Inc. | $1.20 | -9.09% | $10.4M |
| BFRG | Bullfrog AI Holdings Inc. | $0.5689 | -2.55% | $10.5M |
| LTRN | Lantern Pharma Inc. | $0.7107 | -3.57% | $10.6M |
| TOVX | Theriva Biologics Inc. | $0.2157 | -1.69% | $9.9M |
| BLRX | BioLineRx Ltd. | $2.17 | 0.00% | $10.8M |
| PHIO | Phio Pharmaceuticals Corp. | $0.9345 | +1.36% | $10.9M |
| KPTI | Karyopharm Therapeutics Inc. | $0.4274 | -15.38% | $9.7M |
| KPRX | Kiora Pharmaceuticals Inc. | $2.47 | -3.52% | $10.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier